|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
ATE344324T1
(de)
|
1993-09-14 |
2006-11-15 |
Imp Innovations Ltd |
Eotaxin = eosinophil chemotaktisches cytokin
|
|
JP3367581B2
(ja)
|
1993-10-14 |
2003-01-14 |
小野薬品工業株式会社 |
新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
|
|
US6806061B1
(en)
|
1995-01-19 |
2004-10-19 |
Children's Medical Center Corporation |
G protein-coupled receptor gene and methods of use therefor
|
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
|
WO1997024325A1
(en)
|
1995-12-28 |
1997-07-10 |
Takeda Chemical Industries, Ltd. |
DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
|
|
EP0914319B1
(en)
|
1996-05-20 |
2001-11-21 |
Teijin Limited |
Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
|
|
AU6133098A
(en)
|
1997-01-21 |
1998-08-07 |
Merck & Co., Inc. |
3,3-disubstituted piperidines as modulators of chemokine receptor activity
|
|
SK112899A3
(en)
|
1997-02-26 |
2001-05-10 |
Pfizer |
Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
|
|
US6207155B1
(en)
|
1997-05-07 |
2001-03-27 |
Schering Corporation |
Method of eosinophil depletion with antibody to CCR 3 receptor
|
|
GB9711643D0
(en)
|
1997-06-05 |
1997-07-30 |
Janssen Pharmaceutica Nv |
Glass thermoplastic systems
|
|
WO1999036518A1
(en)
|
1998-01-15 |
1999-07-22 |
Btg International Limited |
Ribozymal nucleic acids cleaving ccr5 or cxcr4
|
|
CA2321962C
(en)
|
1998-02-27 |
2014-07-15 |
The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services |
G protein-coupled receptor antagonists
|
|
US6180348B1
(en)
|
1998-04-20 |
2001-01-30 |
Weihua Li |
Method of isolating target specific oligonucleotide ligands
|
|
CA2235420A1
(en)
|
1998-06-17 |
1999-12-17 |
Paolo Renzi |
Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
|
|
US6429308B1
(en)
|
1998-11-24 |
2002-08-06 |
Hisamitsu Pharmaceutical Co., Inc. |
HIV infection inhibitors
|
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
|
IL145401A0
(en)
|
1999-03-24 |
2002-06-30 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
|
AU2001233277B2
(en)
|
2000-02-03 |
2004-06-03 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-ccr2 antibodies and methods of use therefor
|
|
GB2361704C
(en)
|
2000-03-03 |
2006-08-02 |
Cambridge Antibody Tech |
Human antibodies against eotaxin and their use
|
|
US6946546B2
(en)
|
2000-03-06 |
2005-09-20 |
Cambridge Antibody Technology Limited |
Human antibodies against eotaxin
|
|
GB0016138D0
(en)
|
2000-06-30 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
|
US20020147312A1
(en)
|
2001-02-02 |
2002-10-10 |
O'keefe Theresa |
Hybrid antibodies and uses thereof
|
|
US20050124569A1
(en)
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
|
EP2990394A1
(en)
|
2001-11-30 |
2016-03-02 |
Biogen MA Inc. |
Antibodies against monocyte chemotactic proteins
|
|
AR041786A1
(es)
|
2002-03-15 |
2005-06-01 |
Novartis Ag |
Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
|
|
GB0212357D0
(en)
|
2002-05-29 |
2002-07-10 |
Glaxo Group Ltd |
Novel compounds
|
|
JP2006502107A
(ja)
|
2002-07-02 |
2006-01-19 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｃｃｒ−３レセプターアンタゴニストｉｘとしての２，５−置換ピリミジン誘導体
|
|
US7964194B2
(en)
|
2002-11-15 |
2011-06-21 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
|
|
PL378753A1
(pl)
|
2003-02-27 |
2006-05-15 |
F.Hoffmann-La Roche Ag |
Antagoniści receptora CCR-3
|
|
US20050069955A1
(en)
|
2003-06-30 |
2005-03-31 |
Daniel Plaksin |
Antibodies and uses thereof
|
|
AR046594A1
(es)
|
2003-10-16 |
2005-12-14 |
Applied Research Systems |
Usos terapeuticos de variantes de quemoquina
|
|
AU2005214287A1
(en)
|
2004-02-20 |
2005-09-01 |
Genesis Research And Development Corporation Limited |
Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders
|
|
ATE425161T1
(de)
|
2004-05-26 |
2009-03-15 |
Janssen Pharmaceutica Nv |
Mercaptoimidazole als ccr2-rezeptorantagonisten
|
|
KR20070063562A
(ko)
|
2004-09-28 |
2007-06-19 |
얀센 파마슈티카 엔.브이. |
치환 디피페리딘 ｃｃｒ２ 길항제
|
|
AU2006203826A1
(en)
|
2005-01-07 |
2006-07-13 |
Emory University |
CXCR4 antagonists for the treatment of HIV infection
|
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
|
TW200716174A
(en)
|
2005-05-19 |
2007-05-01 |
Centocor Inc |
Anti-MCP-1 antibodies, compositions, methods and uses
|
|
GB0517966D0
(en)
|
2005-09-02 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
|
HUP0500877A2
(en)
|
2005-09-22 |
2007-05-29 |
Sanofi Aventis |
Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
|
|
EP2041568A4
(en)
|
2006-06-15 |
2009-08-12 |
|
CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
|
|
ATE537166T1
(de)
|
2006-10-27 |
2011-12-15 |
Boehringer Ingelheim Int |
Piperidylpropanthiole als ccr3-modulatoren
|
|
HRP20110551T1
(hr)
|
2007-05-30 |
2011-09-30 |
Eli Lilly & Company |
Antagonisti cikličkog peptida cxcr4
|
|
CA2692761C
(en)
|
2007-07-12 |
2013-04-30 |
Chemocentryx, Inc. |
Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
|
|
EP2237798A2
(en)
*
|
2007-12-12 |
2010-10-13 |
Imperial Innovations Limited |
Methods
|
|
HUP0800478A2
(en)
|
2008-07-31 |
2010-03-01 |
Sanofi Aventis |
Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
|
|
WO2010069979A1
(en)
|
2008-12-16 |
2010-06-24 |
Nycomed Gmbh |
Pyran derivatives as ccr3 modulators
|
|
ES2551557T3
(es)
|
2008-12-19 |
2015-11-19 |
Boehringer Ingelheim International Gmbh |
Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
|
|
US8278302B2
(en)
|
2009-04-08 |
2012-10-02 |
Boehringer Ingelheim International Gmbh |
Substituted piperidines as CCR3 antagonists
|
|
ES2528625T3
(es)
|
2009-04-17 |
2015-02-11 |
Janssen Pharmaceutica Nv |
Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2
|
|
US8471004B2
(en)
|
2009-10-07 |
2013-06-25 |
Hoffman-La Roche Inc. |
Bicyclic compounds
|
|
US8445674B2
(en)
|
2009-10-21 |
2013-05-21 |
Hoffmann-La Roche Inc |
Heterocyclyl compounds
|
|
JP5356323B2
(ja)
*
|
2010-07-01 |
2013-12-04 |
富士化学工業株式会社 |
新規な非晶質ボセンタン及びその製造方法
|
|
US20120088769A1
(en)
*
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
EP2646429B1
(en)
|
2010-12-01 |
2014-10-15 |
Janssen Pharmaceutica NV |
4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
|
|
US20140005174A1
(en)
|
2011-03-17 |
2014-01-02 |
Anilkumar G. Nair |
Indole derivatives useful as ccr2 antagonists
|
|
WO2012138880A2
(en)
|
2011-04-07 |
2012-10-11 |
The Brigham And Women's Hospital, Inc. |
Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2)
|
|
AU2012258575B2
(en)
*
|
2011-05-25 |
2017-03-02 |
Intermune, Inc. |
Pirfenidone and anti-fibrotic therapy in selected patients
|
|
DK2723360T3
(en)
|
2011-06-27 |
2017-08-28 |
Univ Pierre Et Marie Curie Paris 6 |
CCR2 antagonist peptides
|
|
US20140336159A1
(en)
*
|
2011-10-07 |
2014-11-13 |
Pulmatrix, Inc. |
Methods for treating and diagnosing respiratory tract infections
|
|
WO2013057545A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Biocon Limited |
Acid addition salts of bosentan
|
|
US8822460B2
(en)
|
2012-04-06 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Fused cyclopentyl antagonists of CCR2
|
|
US20160015786A1
(en)
*
|
2013-03-01 |
2016-01-21 |
Mater Medical Research Institute Limited |
Mobilizing agents and uses therefor
|
|
WO2014143807A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|